Tevogen Bio Holdings Inc. (TVGN) Dividend History

Tevogen Bio Holdings Inc. (TVGN) is a biopharmaceutical company focused on developing innovative therapies, including vaccines and treatments for infectious diseases. The company aims to leverage scientific advancements to address unmet medical needs through its research and development efforts.

15 Independence Boulevard, Suite 410, Warren, NJ, 07059
Phone: 646-807-8832
Website: https://www.tevogen.com

Dividend History

Tevogen Bio Holdings Inc. currently does not pay dividends

Company News

AI Healthcare Boom Gains Speed as Regulators and Innovators Align

The integration of artificial intelligence (AI) into healthcare is accelerating, with 90% of healthcare companies already seeing positive ROI from investments in generative AI. Several companies, including Avant Technologies, Tempus AI, Tevogen Bio Holdings, GE HealthCare Technologies, and Schrödinger, are making advancements in AI-driven healthcare solutions.

Benzinga

Featured Companies: GEHC SDGR TEM
CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

Tevogen Bio announced that CD8 Technology Services has signed a letter of intent for a facility to support Tevogen's cell therapy manufacturing. Tevogen's CEO emphasized the importance of in-house manufacturing for operational efficiency.

GlobeNewswire Inc.
Tevogen Bio Announces 2025 Annual Meeting

Tevogen Bio has finalized an agreement to establish its own cell therapy production facility, which aligns with the company's previously announced forecasts.

GlobeNewswire Inc.
Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility

Tevogen Bio has entered into an agreement with CD 8 Technology Services LLC to develop and/or acquire a turn-key facility to support in-house pre-clinical research and GMP cell therapy production capabilities. This agreement is a key component of Tevogen Bio's long-term strategy to accelerate development timelines, maintain operational agility, and control costs.

Benzinga
Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility

Tevogen Bio has entered into an agreement with CD8 Technology Services LLC to develop and/or acquire a turn-key facility to support in-house pre-clinical research and GMP cell therapy production capabilities. This agreement is a key component of Tevogen's long-term strategy to accelerate development timelines, maintain operational agility, and control costs.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 15:41:23 UTC